Pet/Ct in Prostate Cancer (Clinicians’ Guides to Radionuclide Hybrid Imaging)

Description

This pocket book explains the significant and well-documented impact that PET/CT can have on the management of prostate cancer through the provision of high-quality evidence regarding function and structure. Up-to-date information is supplied on the relevance of PET/CT to diagnosis, treatment planning, and therapy, including the emerging role of PET/CT with PSMA. Readers will also find clear explanation of the relation of the clinical and pathological background to imaging and the value of PET/CT compared with conventional radiological imaging. The book will be an excellent asset for referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. It is published within the Springer series Clinicians’ Guides to Radionuclide Hybrid Imaging, which presents contributions from professionals worldwide who share a common purpose in promoting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.

Table of Contents

1. Acknowledgements
2. Contents
3. Contributors
4. 1: Epidemiology and Clinical Features
5. 1.1 Epidemiology
6. 1.2 Risk Factors
7. 1.3 Clinical Presentation
8. 1.4 Diagnosis
9. 1.5 Staging Procedures and Investigations
10. 1.6 Risk Stratification
11. References
12. 2: Pathology of Prostate Cancer
13. 2.1 Introduction
14. 2.2 Histological Features
15. 2.3 Immunohistochemistry
16. 2.4 Gleason Grading
17. 2.5 Newer Sampling Techniques
18. 2.6 Prognostic Factors
19. 2.7 Molecular Markers
20. References
21. 3: Management of Prostate Cancer
22. 3.1 Localised Prostate Cancer
23. 3.2 Active Surveillance
24. 3.3 External Beam Radiotherapy
25. 3.3.1 Brachytherapy
26. 3.3.2 Radical Prostatectomy
27. 3.4 Metastatic Disease
28. 3.4.1 Corticosteroids
29. 3.4.2 Cytotoxic Chemotherapy
30. 3.4.3 Androgen Receptor Pathway Targeted Agents
31. 3.4.4 Other Agents
32. References
33. 4: Prostate Cancer: Radiological Imaging
34. 4.1 Locoregional Disease
35. 4.1.1 Transrectal Ultrasound
36. 4.1.2 Magnetic Resonance Imaging
37. Morphological Evaluation
38. Diffusion-Weighted MRI
39. Dynamic Contrast-Enhanced MRI
40. MR Spectroscopy
41. 4.1.3 Metastatic Disease
42. 4.1.4 Clinical Guidance
43. Diagnosis
44. Staging
45. Active Surveillance
46. References
47. 5: The Role of PET/CT in Prostate Cancer Management
48. 5.1 Diagnosis of Prostate Malignancies
49. 5.2 Staging of Prostate Malignancies
50. 5.3 Restaging at Disease Recurrence
51. 5.4 Assessing Treatment Response
52. 5.5 Prognostication
53. 5.6 Radiotherapy Planning
54. References
55. 6: Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate C
56. 6.1 Diagnostic Application
57. 6.2 Endoradiotherapy
58. References
59. Index

Editor Biography

Gary Cook is Professor of PET Imaging in the King’s College London and Guy’s & St Thomas’ PET Centre, the head of the Cancer Imaging Department in the Division of Imaging Sciences and Biomedical Engineering, King’s College London, and an honorary consultant at Guy’s & St Thomas’ Hospitals, London, UK. He is a member of the Guy’s and St Thomas’ Hospitals prostate cancer multidisciplinary team, imaging lead for the King’s Health Partners Prostate Cancer Research group, and a member of the UK National Cancer Research Institute Prostate Cancer Clinical Studies Group.